CCSG support of research nurses and clinical research associates dedicated to the conduct and completion of innovative, feasibility or proof-of-principle clinical trials proposed by Cancer Center Programs is critical for SJCRH's continued contribution to pediatric oncology. The Cancer Center leadership is dedicated to protocolspecific research and only trials considered to be of the highest priority are supported by this resource. Our commitment to protocol-based research is illustrated in Summary Table 3 in section 7.0 of this grant application. That table shows that for the index year of October 1, 2005 through September 30, 2006, of 373 patients presenting to St. Jude, 247 (66%) were treated on a therapeutic clinical trial as part of their initial treatment at St. Jude. Eighty-five (85%) of these enrollments were Cancer Center protocols, with the remaining 15% on industry or national protocols. In addition, of the 247 patients enrolling on therapeutic trials during the index year, 56 (23%) were also treated on more than one trial, resulting in 312 therapeutic enrollments. This is largely a result of St. Jude's concentrated effort to recruit previously treated patients to St. Jude for our Phase l/ll Developmental Therapeutics Program. Finally, the 373 patients presenting during the index year also contributed to 549 non-therapeutic enrollments, for a total of 861 protocol enrollments during the index year.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA021765-32
Application #
8054902
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-03-01
Budget End
2011-02-28
Support Year
32
Fiscal Year
2010
Total Cost
$176,726
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Sadighi, Zsila S; Curtis, Elizabeth; Zabrowksi, Jennifer et al. (2018) Neurologic impairments from pediatric low-grade glioma by tumor location and timing of diagnosis. Pediatr Blood Cancer 65:e27063
Wierdl, Monika; Tsurkan, Lyudmila; Chi, Liying et al. (2018) Targeting ALK in pediatric RMS does not induce antitumor activity in vivo. Cancer Chemother Pharmacol 82:251-263
Penkert, Rhiannon R; Hurwitz, Julia L; Thomas, Paul et al. (2018) Inflammatory molecule reduction with hydroxyurea therapy in children with sickle cell anemia. Haematologica 103:e50-e54
Turner, Benjamin L; Brenes-Arguedas, Tania; Condit, Richard (2018) Pervasive phosphorus limitation of tree species but not communities in tropical forests. Nature 555:367-370
Buchman, Cameron D; Chai, Sergio C; Chen, Taosheng (2018) A current structural perspective on PXR and CAR in drug metabolism. Expert Opin Drug Metab Toxicol 14:635-647
Gibbs, E B; Kriwacki, R W (2018) Direct detection of carbon and nitrogen nuclei for high-resolution analysis of intrinsically disordered proteins using NMR spectroscopy. Methods 138-139:39-46
Pui, Ching-Hon; Liu, Yiwei; Relling, Mary V (2018) How to solve the problem of hypersensitivity to asparaginase? Pediatr Blood Cancer 65:
Mukkada, Sheena; Smith, Cristel Kate; Aguilar, Delta et al. (2018) Evaluation of a fever-management algorithm in a pediatric cancer center in a low-resource setting. Pediatr Blood Cancer 65:
Zhong, Bo; Maharaj, Anil; Davis, Abigail et al. (2018) Development and validation of a sensitive LC MS/MS method for the measurement of the checkpoint kinase 1 inhibitor prexasertib and its application in a cerebral microdialysis study. J Pharm Biomed Anal 156:97-103
van Oosterwijk, Jolieke G; Buelow, Daelynn R; Drenberg, Christina D et al. (2018) Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia. J Clin Invest 128:369-380

Showing the most recent 10 out of 6764 publications